Nanohybrid based on antibiotic encapsulated layered double hydroxide as a drug delivery system.
Nanohybrid of cefuroxime (CFO) with layered double hydroxide (LDH) has been prepared, and the rate of dissolution and bioavailability of CFO using nanohybrid as a drug delivery system has been broadly studied. The intercalation process was confirmed by X-ray diffraction, Fourier transform infrared spectroscopy, and thermogravimetric analysis. The CFO contents were found to be 19.0 wt% in the nanohybrid. The release mechanism of CFO was investigated with respect to anion and pH of the dissolution media such as gastric, intestinal and blood simulated media. The effect of pH was evaluated on the release of CFO from nanohybrid, and the dissolution of CFO from the nanohybrid was found to be a slow process at pH 4.0, 6.8, and 7.4. Further the addition of Cl ion and PAM in release media did not affect the release rate of drug at pH 4.0 and 6.8, while at pH 7.4, Cl ion and PAM have significant role on the drug release. At pH 1.2, the release study shows that LDH dissolved in the acidic medium and CFO released in its molecular form. The release behavior suggests two mechanisms that are responsible for the release of CFO from nanohybrid: weathering (dependent on the pH) and ion exchange (highly dependent on the anions). Surface reactions mediated by solid weathering ruled the release in gastric fluid, whereas anion exchange determined CFO release in lysosomal, intestinal, and blood medium. In order to evaluate the drug release mechanism, the released data were fitted by mathematical models describing various kinetic.
Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, Jeddah, Saudi Arabia, drkhanmarwat@gmail.com.
Sher Bahadar
SB
Khan
Khalid A
KA
Alamry
Nedaa A
NA
Alyahyawi
Abdullah M
AM
Asiri
Muhammad Nadeem
MN
Arshad
Hadi M
HM
Marwani
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002444:Cefuroxime / Q000737:chemistry / Q000494:pharmacology; D004055:Differential Thermal Analysis; D016503:Drug Delivery Systems; D006863:Hydrogen-Ion Concentration; D006878:Hydroxides / Q000737:chemistry*; D007700:Kinetics; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D013052:Spectrometry, X-Ray Emission; D017550:Spectroscopy, Fourier Transform Infrared; D013818:Thermogravimetry; D014961:X-Ray Diffraction
D000900:Anti-Bacterial Agents; D006878:Hydroxides; C031356:hydroxide ion; D002444:Cefuroxime